Edwards Lifesciences Reports Third Quarter Results
Edwards Lifesciences reported Q3 2023 sales growth of 10.5% to $1.72B, with TAVR sales up 8.0% to $1.24B and TMTT sales up 44.0% to $207M. EPS was $0.53, up 19% YoY. The company raised its 2023 guidance, including total sales growth to ~11.5% and adjusted EPS to $3.05. Recent highlights include FDA approvals for PASCAL Precision and AUTUS, and positive clinical trial results presented at TCT 2023.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are likely to lift the stock in the near term, while the detailed trial data may influence longer‑term valuation.
Market read
First‑report earnings release with guidance lift; high relevance for equity traders focused on healthcare.
What to watch
Potential supply‑chain constraints or reimbursement pressures could temper growth.
Background
Edwards Lifesciences is a leading structural heart device maker; its quarterly results are closely watched by healthcare investors.
Ticker impact
Edwards Lifesciences reported Q3 sales growth and raised full‑year 2026 sales guidance, a fresh earnings disclosure.
likely upward pressure as investors price in higher sales growth and EPS guidance
Earnings beat and guidance raise are new primary facts that typically drive short‑term buying.
Market effects
Positive for the broader structural heart device sector as Edwards sets a higher growth baseline.
U.S. healthcare stocks may see modest gains on the earnings beat.
Limited to medical device investors; no major macro spillover.
Counterpoint
If guidance is overly optimistic, a pull‑back could occur once detailed unit economics are examined.
Key entities
- companyEdwards Lifesciences
Medical device manufacturer reporting Q3 results.
